Related by context. All words. (Click for frequent words.) 70 ECCMID 69 EORTC NCI AACR 69 AASLD 66 ICAAC 66 SABCS 66 AACR NCI EORTC 66 Liver EASL 65 ECTRIMS 65 #th Annual Interscience 65 Late Breaker 64 ASCO GI 64 ESMO 64 UEGW 64 Clinical Oncology Annual Meeting 63 ICAAC IDSA 63 ASH Annual Meeting 63 CROI 63 st Annual Meeting 62 AASLD Meeting 62 Diabetes EASD 62 League Against Rheumatism 62 Society CTOS 62 EUROGIN 62 ECCO ESMO 61 EuroPCR 61 ISPOR 61 EFNS 61 ORAL Sync 61 AACR #nd Annual Meeting 60 Gastrointestinal Cancers Symposium 60 EORTC NCI AACR Symposium 60 Medical Oncology ESMO 60 Malignant Lymphoma 60 ASCO Annual Meeting 60 ACR ARHP 60 ADA Scientific Sessions 60 Transcatheter Cardiovascular Therapeutics TCT 60 nd Annual Meeting 60 EULAR 60 Connective Tissue Oncology 60 ASCO 60 Digestive Disease Week DDW 60 Molecular Targets 60 #th Interscience Conference 59 AAN Annual Meeting 59 #nd EORTC NCI 59 EASD 59 AACR San Antonio 59 Clinical Microbiology 59 PROSTVAC TM 59 Hematology ASH 59 ARVO 59 AACR EORTC NCI 58 ERA EDTA 58 Genitourinary Cancers Symposium 58 EORTC 58 Hematology ASH Annual Meeting 58 Opportunistic Infections CROI 58 iSBTc 58 Antimicrobial Agents 58 TG MV 58 Urology EAU 58 Hematology Annual Meeting 58 Cardiology ESC Congress 58 Clinical Oncology Gastrointestinal Cancers 57 Hematology Meeting 57 Biological Therapy 57 Cardiology ESC 57 Retroviruses 57 AACR #st Annual Meeting 57 ASBMR 57 International Myeloma Workshop 57 Selective Cardiac Myosin Activator 57 Poster Presentation 57 Selective Cardiac Myosin 57 Venereology EADV 57 Hematology 57 Alzheimer Disease ICAD 57 Clinical Oncology ASCO Annual 57 Infectious Diseases ECCMID 57 CTRC AACR San Antonio 56 Annual Scientific Sessions 56 Respiratory Society 56 Endocrine Society ENDO 56 Hypertension ESH 56 Poster Session 56 Chemotherapy ICAAC 56 Chicago Multidisciplinary Symposium 56 EACTS 56 AACR symposium 56 Allergology 56 Cachexia 56 ECNP 56 vascular disrupting agent 56 Digestive Disease Week 56 #st Annual Meeting 56 Clinical Trial Results 56 Canaccord Adams Hepatitis C 56 Poster Discussion 56 EULAR Annual 56 Rheumatology ACR Annual 55 Phase Ib study 55 AHA Scientific Sessions 55 ASCO GU 55 Arteriosclerosis Thrombosis 55 Liver Diseases AASLD 55 AACR Symposium 55 Therapeutics TCT 55 Hsp# Inhibitor 55 oral FTY# 55 Scientific Sessions 55 Pharmacodynamics 55 Pediatric Academic Societies PAS 55 HCV Protease Inhibitor 55 Arpida Ltd. 55 USpella 55 Neoplasia 55 Breaking Clinical Trials 55 Venereology 55 www.hematology.org 54 Carfilzomib 54 Breast Cancer Symposium SABCS 54 Cancers Symposium 54 European CanCer Organisation ECCO 54 ABCSG 54 TRO# 54 www.aacr.org 54 Related Disorders ICAD 54 th Interscience Conference 54 HCV SPRINT 54 Pharmacoepidemiology 54 ASGT 54 Association EHA 54 Neurological Societies 54 Epileptology 54 Drugs Affecting Lipid 54 AVADO 54 AIR2 Trial 54 Keystone Symposia 54 International Papillomavirus 54 Nephrology Renal Week 54 BiTE R 54 Embryology ESHRE 54 CTRC AACR 54 Phase #/#a 54 AACR 54 Liver Disease AASLD 53 ASCO Breast Cancer 53 Antiviral Activity 53 EORTC NCI 53 J Clin Oncol 53 Cardiostim 53 Liver Diseases 53 NASDAQ CYTK announced 53 Symposium SABCS 53 #nd Annual Meeting 53 Cloretazine ® 53 Developmental Therapeutics Immunotherapy 53 Oral Presentations 53 GTCbio 53 San Antonio Breast Cancer 53 phase IIb study 53 Gastrointestinal Cancer 53 radezolid 53 Safinamide 53 CLARITY study 53 Vascular Biology ATVB 53 Phase 2a Study 53 Solorel TM 53 Poster Presentations 53 ongoing Phase 1b 53 ISTH 53 fosbretabulin 53 Pharmacokinetics 53 Abstract Number 53 Antiviral Research 53 satraplatin Phase 53 Oral Fingolimod 53 Breast Cancer Symposium 53 Annual ICAAC 53 riociguat 53 Dr. McHutchison 53 BRIM3 53 ENDO 53 antibody blinatumomab MT#/MEDI-# 53 EFORT Congress 53 Annual Interscience Conference 53 Gynecologic Cancer Society 53 Tanespimycin 53 Clinical Efficacy 53 Cloretazine R 53 Randomized Phase 53 Autoimmunity 53 Diabetologia 53 AACR Annual Meeting 53 www.asco.org 53 SUCCEED trial 53 PSN# [002] 53 RECORD1 53 pan HDAC inhibitor 53 Innate Immunity 53 ASGCT 53 dose escalation clinical 53 AACR IASLC Joint 53 Scientific Session 53 viral kinetic 53 Endocrine Society #st 53 Clinical Oncology ASCO 53 randomized discontinuation trial 53 BioPartnering Europe 53 RIO Lipids 53 Podium Presentation 53 Dr. Pingpank 53 CIRSE 53 th Annual Interscience 53 Respiratory Viral Infections 52 NO# [002] 52 II Clinical Trial 52 EVEREST II 52 abstracts summarizing 52 Annual Transcatheter Cardiovascular 52 BIOCOM Investor Conference 52 R roscovitine 52 Malignant Mesothelioma 52 RE LY trial 52 Pharmacological Society 52 ASCO abstract 52 BHIVA 52 Genital Infection 52 Preclinical Data 52 Abstract # 52 Metastatic Melanoma 52 Combination REOLYSIN R 52 Inflammatory Arthritis 52 Nordic ACTI 52 EXPAREL ™ 52 Multiple Sclerosis ECTRIMS 52 Heart Failure Society 52 GASTRO 52 Interscience Conference 52 Percutaneous Cardiovascular Interventions 52 Microplasmin 52 Clinical Virology Symposium 52 ISHLT 52 AUA Annual Meeting 52 Environ Health Perspect 52 entitled Synergistic 52 Endovascular Therapy 52 Therapeutics TCT scientific 52 CCX# 52 pharmacokinetic PK 52 Digestive Diseases Week 52 preclinical efficacy 52 ESTRO 52 Aggressive Reduction 52 Gastroenterology Week UEGW 52 Hypertension ASH 52 Xenotransplantation 52 Opportunistic Infections 52 Pirfenidone 52 Haemostasis 52 Therapeutic Radiology 52 TMC# C# 52 LibiGel ® 52 HDAC Inhibitor 52 Oncology ESTRO 52 Oncologic Drugs Advisory 52 Preclinical Efficacy 52 AIDS Vaccine 52 Phase 2b Clinical Trial 52 CLL8 52 BIO InvestorForum 52 Antiviral Therapy 51 SUTENT ® 51 Preclinical Study 51 Related Viruses 51 Phase Ib clinical 51 Safety Tolerability 51 BiTE antibody MT# 51 Oligonucleotide Therapeutics Society 51 Acute Ischemic Stroke 51 LUX Lung 51 phase IIa 51 liposome injection 51 HyQ 51 Phase Ib II 51 ON #.Na 51 Cambridge Healthtech Institute 51 ganetespib 51 Solid Tumors 51 Hematological 51 Diabetic Macular Edema DME 51 HFSA Annual 51 #rd Annual CTRC 51 Phase III psoriasis 51 REG2 51 DDW 51 ESHRE 51 ASCO Genitourinary Cancers Symposium 51 PreCISe 51 Anticancer Drug 51 BCIRG 51 oral JAK1 51 ECASS 51 Intensive Care Medicine 51 CombAT 51 Natalizumab 51 AA Amyloidosis 51 teriflunomide 51 Neuropathic Pain 51 Phase 1b trial 51 CRMD# 51 Pooled Analysis 51 BioContact Quebec 51 ILLUMINATE 51 darinaparsin ZIO 51 ENDEAVOR III 51 Ambrisentan 51 Prostate Cancer Symposium 51 Preclinical Development 51 recurrent GBM 51 Antimicrobial Chemotherapy 51 Endocrine Society Annual Meeting 51 HUPO 51 FDA Oncologic Drugs 51 ELACYT 51 Transcatheter Cardiovascular Therapeutics 51 Pivotal Trial 51 annual Transcatheter Cardiovascular 51 PROVENGE sipuleucel T 51 Hematological Malignancies 51 AACR NCI EORTC Molecular 51 randomized controlled Phase 51 Cancer iSBTc 51 Systemic Sclerosis 51 Dendritic Cells 51 Dr. Yatscoff 51 Cancer Res 51 PEG SN# 51 PROactive Study 51 Oral Abstract 51 Pharmacoeconomics 51 Lysosomal Disease Network 51 Abstracts 51 fidaxomicin Phase 3 51 OXi# 51 Trandolapril 51 phase 2a 51 Oral Presentation 51 Dasatinib 50 Interventional Radiology SIR 50 Therapeutics Roundtable 50 #:#-# [031] 50 obatoclax 50 Cancer Immunotherapy 50 ExTRACT TIMI 50 VEITHsymposium 50 Phase 2b 50 ACR ARHP Annual 50 neratinib 50 Molecular Medicine Tri 50 phase Ib 50 EndoTAG TM -1 50 PROSTASCINT R 50 BOLDER II 50 AEZS 50 Juergen Engel Ph.D. 50 Edge STudy 50 ASCO Gastrointestinal Cancers Symposium 50 vidofludimus 50 Clinical Oncologists 50 delafloxacin 50 Phase 2b trial 50 SPIRIT IV 50 number NCT# ClinicalTrials.gov 50 Stem Cell Research ISSCR 50 Kinase Inhibitor 50 Ranolazine 50 Fifth Decennial International 50 compound AEZS 50 Rheumatology Annual Meeting 50 Arch Neurol 50 Photocure ASA 50 multicenter trials 50 www.novelos.com 50 Endovascular Therapy ISET 50 novel histone deacetylase 50 Potent Antiviral Activity 50 AACR Meeting 50 phase IIb 50 Pediatric Academic Societies 50 Plenary Session 50 Belimumab 50 Neuropsychopharmacology 50 CALGB # [002] 50 multicenter prospective 50 Interventional Radiological Society 50 Elvitegravir 50 Lung Transplantation 50 velafermin 50 Nexavar sorafenib 50 DIA EuroMeeting 50 Paediatric Infectious Diseases 50 Randomized Double blind 50 GW# [003] 50 Stent Thrombosis 50 Phase 2a 50 Multicenter 50 CALGB 50 SA FC# 50 Rheumatology EULAR 50 Refractory Angina 50 Oncology ASTRO 50 HIV Pathogenesis 50 ORMD 50 Cardiac Outcomes 50 Thoracic Oncology 50 NASDAQ CXSP announced 50 Biennial Meeting 50 Suppl. 50 Phase III ADT 50 AACR Frontiers 50 preclinical pharmacokinetic 50 Therapeutic Targets 50 mitogen activated ERK kinase 50 Endocrine Society #nd 50 HIF PHI 50 MEND CABG 50 Experimental Biology EB 50 Metabolic Disorders 50 Targeted Anticancer Therapies 50 EADV 50 Addex Pharmaceuticals SIX ADXN 50 MERLIN TIMI 50 Clinical Trial Data 50 Rheumatology Annual 50 abstracts 50 dose escalation trial 50 Breaking Clinical Trial 50 pharmacokinetic PK study 50 trastuzumab DM1 50 Phase #/#a trial 50 PERSEUS 50 Retina Specialists 50 Genitourinary Cancer 50 alpha antagonist 50 HepaSphere 50 Gastroenterology ACG Annual 50 Phase 1b 50 CEQ# 50 Controlled Release 50 Targeted Therapies 50 Hedgehog Pathway Inhibitor 50 CIBMTR 50 KRN# 50 ABRF 50 Advanced Neuroendocrine Tumors 49 HCV NS5B polymerase 49 Prolongs Survival 49 Phase Ib 49 abstr 49 Glufosfamide 49 evaluating tivozanib 49 recurrent glioma 49 Liver Disease 49 European CanCer Organisation 49 Hagop M. 49 Marrow Transplantation 49 depsipeptide 49 American Thoracic Society 49 http:/www.genmab.com 49 multicenter Phase II 49 Phase 2a trial 49 Dose Escalation 49 Melanoma Skin Cancers 49 randomized Phase III 49 AVERROES 49 IL# PE#QQR 49 oral prodrug 49 Mineral Research ASBMR 49 Phase IIB 49 Diabetic Macular Edema 49 Phase III ALLEGRO 49 Virulizin ® 49 Double Blind Placebo 49 Presents Preclinical Data 49 Cancer Vaccines 49 Glucosamine Chondroitin Arthritis 49 Boceprevir 49 histone deacetylase HDAC inhibitor 49 Nephrology Annual Meeting 49 Annual BIO 49 novel VDA molecule 49 Announces Poster Presentations 49 See CLINICAL PHARMACOLOGY 49 Xanafide 49 HORIZONS AMI trial 49 ASM Biodefense 49 Relapsing Multiple Sclerosis 49 Cellular Therapy ISCT 49 ISSWSH 49 Pharmaceutical Scientists AAPS 49 CA4P 49 Hormone Refractory Prostate Cancer 49 targeting CD# 49 VESTASYNC 49 BioCentury Future Leaders 49 multicenter randomized Phase 49 GTCbio 3rd 49 Removab 49 HQK 49 Phase 2a clinical 49 eltrombopag 49 Infectious Disease ECCMID 49 phase IIb clinical 49 PCK# 49 Novel Oral 49 antibody MT# 49 Hematologic Malignancies 49 International OARSI 49 Chronic Lymphocytic Leukemia 49 CRLX# 49 Femara letrozole 49 Cardiovascular Anesthesiologists 49 axitinib 49 CYT# potent vascular disrupting 49 Cardiovascular Interventions 49 Nasdaq IDRA today 49 Neck Cancer 49 Cell Transplant 49 Therapeutic Radiation 49 Romidepsin 49 BioEquity Europe 49 Deutsches Herzzentrum 49 Ocrelizumab 49 Human Brain Mapping 49 Plicera 49 Cardiology Heart Failure 49 Clavis Pharma 49 dual endothelin receptor antagonist 49 America HFSA 49 Breast Surgeons ASBS 49 CAMMS# 49 Epilepsy Society 49 FASEB J. 49 CardioBip 49 Randomized Phase II 49 Initiated Phase 49 TRANSFORMS 49 Bortezomib 49 Prostate AdenoCarcinoma Treatment 49 ADVANCE PD 49 Personalized Immunotherapy 49 Advanced Renal Cell 49 Thrombosis 49 Aplidin 49 assessing T DM1 49 Ann Oncol 49 Cellular Immunology 49 decitabine 49 sipuleucel T 49 PROSTVAC ® 49 APOPTONE 49 Molecular Pathology 49 Arch Surg 49 EMBO J. 49 ESCRS 48 ACC.# 48 Angiolix 48 plenary lectures 48 Tumor Biology 48 TACI Ig 48 Haematology 48 Ocular Diseases 48 Molecular Origins 48 PI3 kinase inhibitors 48 AAPS Annual Meeting 48 huN# DM1 48 Spine Arthroplasty Society 48 tanespimycin 48 Amrubicin 48 Traficet EN 48 Clinical Oncology 48 Sym# 48 JAK2 Inhibitor 48 Genome Biology 48 Multilateral Initiative 48 non nucleoside inhibitor 48 HuMax CD4 48 Cancer Therapeutic 48 ELSO 48 STEEPLE 48 Female Urology 48 Ocular Pharmacology 48 Ophthalmic Drugs Advisory 48 Brentuximab Vedotin SGN 48 CYT# 48 ANN INTERN MED 48 Ophthalmology ARVO 48 REALITY Trial 48 FOLOTYN ® 48 RESTORE CLI 48 Functional Neurosurgery 48 HCV RESPOND 2 48 HuMax EGFr 48 CUSTOM II 48 Vaccine Adjuvant 48 clevidipine 48 Clinical Oncology ASCO Gastrointestinal 48 tolerability profiles 48 pharmacodynamic properties 48 Bazedoxifene 48 metastatic castration resistant 48 AVN# Phase 48 Phase #b/#a clinical 48 AAPM 48 Sipuleucel T 48 LD Micro 48 Tesetaxel 48 INCB# [001] 48 REACH Registry 48 EAACI 48 TASKi2 48 Experimental Biology Annual Meeting 48 omacetaxine mepesuccinate 48 Active Biotech NASDAQ OMX 48 pertuzumab 48 comparing alemtuzumab 48 CR# vcMMAE 48 ROCKET AF 48 varespladib 48 HFSA 48 seliciclib 48 phase IIb trial 48 Retina Specialists ASRS 48 ALB # 48 rALLy trial 48 www.nejm.org 48 Perifosine 48 Pazopanib 48 Continence Society 48 Liver Meeting 48 Reverset 48 EUROPEAN BIOTECHNICA AWARD 48 Molecular Therapy 48 Scientific Meeting 48 AEG# 48 Vaccine Immunology 48 Allovectin 7 ® 48 EOquin TM 48 Therapeutic Advances 48 ALN TTR 48 Rasilamlo 48 Randomized Phase III 48 Int J Epidemiol 48 CARE HF 48 ImmunoVEX HSV2 48 taxane resistant 48 BZL# 48 Meets Primary Endpoint 48 PEGylated interferon beta 1a 48 ASTMH 48 Peer Reviewed Journal 48 RGB # 48 Romiplostim 48 Onrigin 48 Outcomes Research ISPOR 48 website www.asco.org 48 SMi 48 SYMMETRY trial 48 phase IIa clinical 48 Randomized Comparison 48 DDW ® 48 phase IIIb 48 trabectedin 48 orally inhaled migraine 48 Kahalalide F 48 University Hospital Gasthuisberg 48 INCB# [002] 48 NSTI Nanotech 48 Genta Incorporated OTCBB GETA 48 iclaprim 48 Phase 2a Clinical Trial 48 Am J Pathol 48 Neurology AAN 48 RNAi Therapeutic 48 Denufosol 48 Immunodeficiencies 48 metaglidasen 48 Neurochemistry 48 OARSI 48 BOLDER 48 ACM SIGCOMM 48 Haemostasis ISTH 48 Am J Epidemiol 48 IRX 2 48 Cardiology 48 Room #AB [002] 48 transthyretin TTR mediated amyloidosis 48 INGN 48 Novel Inhibitor 48 PI3K/mTOR 48 GRNCM1 48 EGS# 48 trastuzumab DM1 T DM1 47 oral ridaforolimus 47 SAR# [004] 47 PFO migraine 47 Final Appraisal Determination 47 GOUT 47 journal Transplantation 47 clinical pharmacology studies 47 BRIM2 47 Microbiology ASM 47 journal Nature Immunology 47 Experimental Medicine 47 Gynecological Cancer 47 Immunogenetics 47 Aflibercept 47 Immunology Annual Meeting 47 journal Antimicrobial Agents 47 Hyperthermic Oncology ESHO 47 ERSPC 47 Free Full Text 47 vinca alkaloid 47 LBH# 47 Rheumatology 47 & Immunology AAAAI 47 Xelox 47 Sangamo BioSciences Announces 47 Proc Am Soc 47 Anti Tumor 47 epigenetic therapies 47 Inc. Nasdaq VRUS 47 Investigative Pathology 47 EURIDIS 47 Talabostat 47 Phase 2b RESTORE CLI 47 Neurological Societies EFNS 47 Patient Recruitment 47 Telaprevir 47 Gene Therapy ASGT 47 RTOG 47 J Clin Endocrinol Metab 47 Nephrol Dial Transplant 47 BioPharm America 47 Recurrent Chest Wall 47 Fondaparinux 47 ICAD 47 ACOMPLIA R 47 Cytokinetics Incorporated NASDAQ CYTK 47 Urology EAU Congress 47 Aryplase 47 SYNTAX trial 47 prostate cancer mCRPC 47 Zenvia Phase III 47 ENDEAVOR IV 47 Alpharadin 47 Nasdaq CLSN 47 AABB Annual Meeting 47 Macula Society 47 FOCIS 47 perifosine KRX 47 Interventional Cardiologists 47 Cardiology Scientific Sessions 47 elacytarabine 47 angiogenesis inhibitor 47 TORISEL TM 47 Long Awaited Reality 47 AVAX 47 BiTE ® 47 Bipolar Disorders 47 Angiology 47 Castration Resistant Prostate Cancer 47 Acute Myocardial Infarction 47 Apoptone 47 Fondation Ipsen 47 Preclinical Studies 47 Nephrology ASN Renal 47 SCCHN 47 JAK1 47 Deforolimus 47 Medical Oncology 47 NICE SUGAR 47 anticancer compound 47 journal Arteriosclerosis Thrombosis 47 ANTEGREN 47 Completes Patient Enrollment 47 huC# DM4 47 RADIANT 47 BIBW 47 Experimental Neurology 47 registrational 47 CAPRISA 47 Inc. NASDAQ HEPH 47 Ceflatonin 47 ASHG 47 Mass Spectrometry ASMS 47 Panzem R 47 aclidinium bromide 47 Val HeFT 47 Daclizumab 47 YONDELIS 47 ASTRO Annual Meeting 47 Arrhythmias 47 TAXUS ATLAS 47 sulodexide 47 Oligonucleotides 47 alvimopan 47 Thromb Haemost 47 Neurological Surgeons AANS 47 Clinical Chemistry 47 ClinicalTrials.gov 47 CHEST 47 Enzastaurin 47 Phase 2b study 47 Angiogenesis 47 http:/www.hematology.org 47 Central Retinal Vein 47 PRECISE 47 Monoclonal Antibodies 47 SCAI Annual 47 Elagolix 47 Candesartan 47 Fabry Disease 47 Colposcopy 47 IADR 47 Phase Ib Clinical Trial 47 Meta Analysis 47 mRCC 47 PXD# 47 RIBBON 47 Myelodysplastic Syndromes 47 RVX 47 Chemophase 47 Wound Healing Society 47 #:#-# [023] 47 Recombinant Human 47 J Am Coll 47 Hexvix 47 Physiological Society 47 OvaRex R 47 Radiology ECR 47 Retrovirus Conference 47 Br J Cancer 47 OMP #M# 47 ENMD # 47 Windhover Therapeutic Area 47 Nephrology CJASN 47 journal Pediatric Allergy 47 Antiviral 47 metastatic hormone refractory 47 Leukocyte Biology 47 YONDELIS R 47 Neuro Oncology SNO 47 forodesine 47 Cancer Cachexia 47 orally administered inhibitor 47 Cardiovascular Therapeutics 47 BioNumerik 47 Immunotherapeutic 47 American Roentgen Ray 47 ESHO 47 Gastroenterology ACG 47 Printable slides 47 OLYMPIA registry 47 SIR Spheres 47 Kantarjian 47 Nasdaq ENZN 47 Movement Disorder 47 trastuzumab Herceptin ® 47 prospective multicentre 47 Artificial Organs 47 ENESTnd 46 preclinically 46 Pyridorin 46 Intervention Effectiveness 46 Respirology 46 subanalysis 46 Opexa 46 panobinostat 46 Overactive Bladder OAB 46 Clinical Practice Guideline 46 label multicenter Phase 46 Inflammatory Bowel Diseases 46 Autoimmune Diseases 46 AAG geldanamycin analog 46 Diabet Med 46 Osseointegration 46 oral rivaroxaban 46 sunitinib malate 46 ZYBRESTAT fosbretabulin 46 Cervical Pathology 46 Clinical Chemistry AACC 46 ASSERT 46 www.thelancet.com 46 immatics 46 ASTEROID 46 HORIZONS AMI 46 conference.com 46 anti amnesic 46 IASLC 46 selective inhibition 46 MASCC 46 MT# MEDI 46 Br J Haematol 46 sorafenib Nexavar 46 Guanilib 46 subgroup analyzes 46 XL# SAR# 46 Myeloproliferative Disorders 46 Lenocta 46 Tumor Microenvironment 46 Liposomal 46 Cancer Therapeutics 46 Radiopharmaceutical 46 HDAC Inhibitors 46 ARBITER 6 46 CTAP# Capsules 46 Cardio Thoracic Surgery 46 ASCRS 46 Phase III Trials 46 RE LY 46 PROTECT AF 46 Vertex telaprevir 46 BARI 2D 46 AGBT 46 Temsirolimus 46 Varespladib 46 cediranib 46 NASDAQ SLXP today 46 Bone Marrow Transplantation 46 gastrointestinal stromal tumors GIST 46 Aplidin R 46 ExL Pharma 46 mCRC patients 46 Hoyoung Huh MD Ph.D. 46 Quinamed 46 MT#/MEDI-# 46 Vascular Annual Meeting 46 Pediatric Endocrinology 46 Medicinal Chemistry Letters 46 Gastrointestinal Oncology 46 Arch Intern Med 46 SAEM Annual Meeting 46 TLR antagonists 46 MERIT ES 46 Endocrine Practice 46 BioFinance 46 Azedra 46 J. Mazzo Ph.D. 46 J.P. Morgan Healthcare 46 AIDAC 46 Inc. Nasdaq IMGN 46 Liver Transplantation 46 Interventional Therapies 46 Pemetrexed 46 enzastaurin 46 TIMI Study Group 46 Zarnestra 46 Paediatric Endocrinology 46 Vascular Medicine 46 Nasdaq ALXN 46 Radiation Oncology ASTRO 46 romidepsin 46 INSPIRE Trial Phase III 46 ixabepilone 46 ThermoDox ® clinical 46 sorafenib tablets 46 www.pranabio.com 46 EchoCRT 46 Marie Claude Morice 46 Archexin 46 NAASO 46 trastuzumab emtansine T DM1 46 Physiology Seminar 46 Dr. Gulfo 46 Human Molecular Genetics 46 Ampligen ® 46 Blinatumomab 46 perifosine 46 Epilepsia 46 Tarvacin TM 46 Psychopharmacology 46 Biodefense Vaccines 46 substudy 46 atrasentan 46 EMBO Journal 46 Molecular Markers 46 proteasome inhibitor 46 Certican 46 Pivotal Clinical Trial 46 Menopause Society NAMS 46 alvespimycin 46 Proxinium TM 46 Delcath Phase III 46 Phase III placebo controlled 46 Hematology ASH Meeting 46 standard chemotherapy regimen